FIELD: medicine.
SUBSTANCE: group of inventions refers to a composition for treating inflammation or treating autoimmune disorders containing an antibody which binds to an AGE-modified protein on a cell, and an anti-inflammatory antibody. Group of inventions also relates to a method of treating an inflammation or autoimmune disorders, comprising administering an antibody, which binds to AGE-modified protein on cell, where said treatment includes destruction of aging cells.
EFFECT: group of inventions provides treating the inflammation and autoimmune disorders.
26 cl, 1 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGE ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2766209C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) | 2017 |
|
RU2728964C2 |
| DITRA MODELS IN NON-HUMAN ANIMALS AND THEIR USE | 2019 |
|
RU2804448C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
| IMMUNOGLOBULIN WITH TANDEM ARRANGEMENT OF FAB FRAGMENTS AND APPLICATION THEREOF | 2014 |
|
RU2769133C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2798348C2 |
| THERAPEUTIC USE OF INHIBITORS OF T-CELL ACTIVATION OR STIMULATION | 2016 |
|
RU2779308C2 |
| COMPOSITIONS OF ANTI-CD6 ANTIBODIES AND METHODS OF TREATING AND REDUCING NEGATIVE CONSEQUENCES OF CORONAVIRUS, INCLUDING COVID-19 | 2021 |
|
RU2828013C1 |
